{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:44:42Z","timestamp":1781873082626,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","award":["IACUC-2105045"],"award-info":[{"award-number":["IACUC-2105045"]}],"id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018123","name":"Society for Research on Adolescence","doi-asserted-by":"publisher","award":["PRJNA1171438"],"award-info":[{"award-number":["PRJNA1171438"]}],"id":[{"id":"10.13039\/100018123","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273840"],"award-info":[{"award-number":["82273840"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073754"],"award-info":[{"award-number":["82073754"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jpet.2025.103570","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T09:55:25Z","timestamp":1743587725000},"page":"103570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhanced efficiency of MHC class II tumor neoantigen vaccines with a novel CD4+ T-cell helper epitope"],"prefix":"10.1016","volume":"392","author":[{"given":"Qiuli","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiumin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7370-4330","authenticated-orcid":false,"given":"Hong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103570_bib1","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103570_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and regulation of TH cells: a balancing act for cancer immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpet.2025.103570_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3390\/pharmaceutics15020452","article-title":"Peptide vaccines in melanoma: chemical approaches towards improved immunotherapeutic efficacy","volume":"15","author":"Biri-Kov\u00e1cs","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpet.2025.103570_bib4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jpet.2025.103570_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-021-01467-8","article-title":"Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion","volume":"20","author":"Cai","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jpet.2025.103570_bib6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jpet.2025.103570_bib7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2005.02.003","article-title":"Primary antitumor immune response mediated by CD4+ T cells","volume":"22","author":"Corthay","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.jpet.2025.103570_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamaoncol.2015.5482","article-title":"Association of depressed anti-HER2 T-helper type 1 response with recurrence in patients with completely treated HER2-positive breast cancer: role for immune monitoring","volume":"2","author":"Datta","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jpet.2025.103570_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature10803","article-title":"Expression of tumour-specific antigens underlies cancer immunoediting","volume":"482","author":"DuPage","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103570_bib10","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1172\/JCI67428","article-title":"CD4+ follicular helper T cell infiltration predicts breast cancer survival","volume":"123","author":"Gu-Trantien","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jpet.2025.103570_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103570_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.apsb.2018.06.005","article-title":"Adapting liposomes for oral drug delivery","volume":"9","author":"He","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.jpet.2025.103570_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jpet.2025.103570_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103570_bib15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103570_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41573-023-00873-5","article-title":"Author correction: identification of neoantigens for individualized therapeutic cancer vaccines","volume":"23","author":"Lang","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpet.2025.103570_bib17","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1021\/acsami.7b18277","article-title":"Cervical cancer HeLa cell autocrine apoptosis induced by coimmobilized IFN-\u03b3 plus TNF-\u03b1 biomaterials","volume":"10","author":"Li","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.jpet.2025.103570_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nm.3773","article-title":"High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma","volume":"21","author":"Linnemann","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jpet.2025.103570_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155189","article-title":"Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines","volume":"11","author":"Martin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2025.103570_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103570_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jpet.2025.103570_bib22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature25145","article-title":"Corrigendum: an immunogenic personal neoantigen vaccine for patients with melanoma","volume":"555","author":"Ott","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103570_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jpet.2025.103570_bib24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jpet.2025.103570_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103570_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jpet.2025.103570_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jpet.2025.103570_bib28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jpet.2025.103570_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.immuni.2019.12.007","article-title":"Regulatory T cells restrain interleukin-2- and blimp-1-dependent acquisition of cytotoxic function by CD4+ T cells","volume":"52","author":"\u015aledzi\u0144ska","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jpet.2025.103570_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2018.05.021","article-title":"Nitrated T helper cell epitopes enhance the immunogenicity of HER2 vaccine and induce anti-tumor immunity","volume":"430","author":"Tian","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jpet.2025.103570_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.canlet.2020.05.016","article-title":"Corrigendum to\u201cPDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1\/PDL1 pathway and activating PDL1-specific immune responses\u201d [Canc. Lett. 476 (2020) 170-182]","volume":"499","author":"Tian","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jpet.2025.103570_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004022","article-title":"CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1\/PD-L1 immunotherapy","volume":"10","author":"Xiao","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jpet.2025.103570_bib33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103570_bib34","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.4049\/jimmunol.1401571","article-title":"CD4+ T cell help selectively enhances high-avidity tumor antigen-specific CD8+ T cells","volume":"195","author":"Zhu","year":"2015","journal-title":"J Immunol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525397831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525397831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:01:16Z","timestamp":1777420876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525397831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0022356525397831"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103570","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced efficiency of MHC class II tumor neoantigen vaccines with a novel CD4+ T-cell helper epitope","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103570"}}